University Medical Center Groningen, Department of Hematology, the Netherlands.
Haga Teaching Hospital, Department of Hematology, the Netherlands.
Crit Rev Oncol Hematol. 2022 Mar;171:103581. doi: 10.1016/j.critrevonc.2022.103581. Epub 2022 Jan 7.
One possible side effect of thrombopoietin receptor agonists in immune thrombocytopenia is thrombosis. Our aim is to systematically review whether patients with ITP that were treated with a TPO-RA have an increased risk for thrombosis as compared to ITP patients without TPO-RA. Patients in the intervention group were required to receive TPO-RA therapy. The primary outcome was the incidence of thromboembolic events. Eleven studies were included in the pooled analysis. More thromboembolic events were noted in the TPO-RA group than in the control group: 25 compared to 4. Ten out of 11 studies showed a relative risk greater than 1. However, none of these individual risk ratios was statistically significant. The meta-analysis showed a RR of 1.82 [95 % CI 0.78-4.24]. Our findings indicate there is a non-significant higher chance of thrombosis in ITP patients with TPO-RA treatments versus ITP patients without TPO-RA treatment.
血小板生成素受体激动剂在免疫性血小板减少症中的一个可能副作用是血栓形成。我们旨在系统地回顾接受 TPO-RA 治疗的 ITP 患者与未接受 TPO-RA 治疗的 ITP 患者相比，是否有更高的血栓形成风险。干预组的患者需要接受 TPO-RA 治疗。主要结局是血栓栓塞事件的发生率。共有 11 项研究纳入汇总分析。TPO-RA 组的血栓栓塞事件发生率高于对照组：25 例比 4 例。11 项研究中有 10 项显示相对风险大于 1。然而，这些个体风险比均无统计学意义。荟萃分析显示 RR 为 1.82[95%CI0.78-4.24]。我们的研究结果表明，与未接受 TPO-RA 治疗的 ITP 患者相比，接受 TPO-RA 治疗的 ITP 患者发生血栓的几率有升高，但无统计学意义。
